HTBX News and Press, Heat Biologics Inc. From 01/01/22

Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...

Heat Biologics (NASDAQ:HTBX) has executed a merger agreement to acquire Elusys Therapeutics, manufacturer of ANTHIM (obiltoxaximab) Injection, pursuant to which Elusys will merge into a wholly owned subsidiary of Heat. HTBX shares up 1.5% premarket at $4.06. The acquisition is expected to clo...

DURHAM, N.C., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NASDAQ: HTBX) , a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced it has executed a definitive ...

Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...

Heat Biologics (NASDAQ:HTBX) has unveiled its new RapidVax cellular vaccine platform at the 2021 World Antiviral Congress. Shares up 5.8% premarket at $4.60. RapidVax is designed to enable an accelerated response to a wide variety of infectious agents by providing a flexible &#...

Designed for rapid “plug and play” programming and stockpiling against emerging infectious agents and viral mutations Emergence of Omicron and other COVID-19 variants underscores the need for a rapid, safe, and effective response to potential biological threats ...

Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...

Heat Biologics (NASDAQ:HTBX): Q3 GAAP EPS of -$0.30 in-line. Revenue of $0.5M (-41.2% Y/Y) beats by $0.12M. Press Release For further details see: Heat Biologics EPS in-line, beats on revenue

DURHAM, N.C., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NASDAQ: HTBX) , today provided strategic, financial, and operational updates for the third quarter ended September 30, 2021. Jeff Wolf, Chief Executive Officer of Heat, comment...

Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...